Federal Register / Vol. 73, No. 180 / Tuesday, September 16, 2008 / Notices 53433 

efficiency, high throughput systems for 

protein production or analysis at lower 

cost and ease of scale-up would be 

potential licensors of this technology. 

Development Status: Late Stage— 

Ready for Production. 

Inventors: Joseph Shiloach (NIDDK), 

Pratik Jaluria (NIDDK). 

Related Publication: P. Jaluria et al. 

Application of microarrays to identify 

and characterize genes involved in 

attachment dependence in HeLa cells. 

Metab Eng. 2007 May;9(3):241–251. 

Patent Status: PCT Application No. 

PCT/US2007/018699 filed 24 Aug 2007, 

which published as WO 2008/024459 

on 28 Feb 2008; claiming priority to 24 

Aug 2006 (HHS Reference No. E–149– 

2006/2–PCT–01). 

Licensing Status: Available for 

exclusive or non-exclusive licensing. 

Licensing Contact: Peter A. Soukas, 

J.D.; 301–435–4646; 

soukasp@mail.nih.gov. 

Collaborative Research Opportunity: 

The National Institute of Diabetes and 

Digestive and Kidney Diseases, 

Biotechnology Core Laboratory, is 

seeking parties interested in 

collaborative research projects directed 

toward the use of this technology with 

cells for drug and vaccine production 

and development, including growth 

optimization, production and product 

recovery processes. For more 

information, please contact Dr. Joseph 

Shiloach, josephs@intra.niddk.nih.gov, 

or Rochelle S. Blaustein at 

Rochelle.Blaustein@nih.gov. 

In Vitro Model for Hepatitis C Virion 

Production 

Description of Technology: This 

invention provides an in vitro hepatitis 

C virus (HCV) replication system that is 

capable of producing viral particles in a 

culture medium. Hepatitis C is a major 

public health problem, the development 

of therapeutics for which has been 

hampered by a lack of a robust model 

system to study the complete viral life 

cycle. This invention provides a new 

model system for the complete 

replication cycle of hepatitis C virus and 

virion production, assembly and release. 

The model is useful for screening 

antiviral agents against HCV. 

A full length HCV construct, CG1b of 

genotype 1b which is known to be 

infectious, was placed between two 

ribozymes designed to generate the 

exact 5′ and 3′ ends of HCV when 

cleaved. Using this system, HCV 

proteins and positive and negative RNA 

strands have been shown to reproduce 

intracellularly, and viral particles that 

resemble authentic HCV virions are 

produced and secreted into the culture 

medium. 

The patent application includes 

claims directed toward the following: A 

construct comprising specific nucleic 

acid sequences including HCV genotype 

1b, genotype 1a, genotype 2a or 

potentially other genotypes; a method 

for identifying a cell line that is 

permissive for infection with HCV; a 

method for propagating HCV in vitro; a 

method for screening agents capable of 

modulating HCV replication or activity; 

a method for testing the level of HCV 

replication or activity; a HCV vaccine 

comprising HCV virus particles. 

Applications: The model offers a 

novel method for investigating the 

entire HCV life cycle including 

replication and pathogenesis and is 

useful for high-throughput antiviral 

screening. This technique may also be 

useful for making infectious particles 

that are useful in the production of HCV 

vaccines. 

Advantages: This system provides a 

new, stable and efficient cell culture 

model to further study the life cycle and 

biology of HCV, and to test potential 

therapeutic targets for hepatitis C. This 

model has also been used to generate in 

cell culture HCV strains infectious for 

chimpanzees, the only experimental 

animal susceptible to infection with the 

hepatitis C virus, a critical step in the 

development of new vaccines for 

Hepatitis C. 

Market: Hepatitis C virus (HCV) 

chronically infects approximately 200 

million people worldwide and increases 

the risk of developing cirrhosis and 

hepatocellular carcinoma. This 

technology would be useful for studying 

the HCV life cycle, screening for 

therapeutic agents against multiple HCV 

strains, including Genotype 1a, 1b and 

2a, and the development of HCV 

vaccines. HCV genotypes 1 and 2 are the 

major genotypes with worldwide 

distribution; they are known to be 

associated with different clinical 

profiles and therapeutic responses. 

Hence, the model may be used to screen 

for varying levels of effectiveness of 

therapeutics against the major HCV 

genotypes. 

Development Status: This technology 

is available for use in diagnostics, drug/ 

vaccine discovery, production and 

development. Current work is directed 

toward studies into the HCV life cycle 

and replication and the pathogenesis of 

HCV screening for antiviral agents 

against multiple HCV strains. This 

model has been used to generate in cell 

culture HCV strains infectious for 

chimpanzees, the only experimental 

animal susceptible to infection with the 

hepatitis C virus, a critical step in the 

development of new vaccines for 

Hepatitis C. Future work may be 

directed toward the use of this system 

for development of vaccine candidates 

against HCV. 

Inventors: T. Jake Liang and Theo 

Heller (NIDDK). 

Related Publications: 

1. Z. Hu et al. Altered proteolysis and 

global gene expression in hepatitis B 

virus X transgenic mouse liver. J Virol. 

2006 Feb;80(3):1405–1413. 

2. T. Heller et al. An in vitro model 

of hepatitis C virion production. Proc 

Natl Acad Sci USA. 2005 Feb 

15;102(7):2579–2583. 

Patent Status: U.S. Patent Application 

No. 11/664,375 filed 30 Mar 2007, 

claiming priority to 30 Sep 2004 (HHS 

Reference No. E–324–2004/3–US–02). 

Licensing Status: Available for 

exclusive or non-exclusive licensing. 

Licensing Contact: Peter A. Soukas, 

J.D.; 301–435–4646; 

soukasp@mail.nih.gov. 

Collaborative Research Opportunity: 

The National Institute of Diabetes and 

Digestive and Kidney Diseases, Liver 

Diseases Branch, is seeking parties 

interested in collaborative research 

directed toward molecular strategies for 

vaccine and antiviral development, and 

animal models of viral hepatitis C. For 

more information, please contact Dr. T. 

Jake Liang at 301–496–1721 or 

jliang@nih.gov or Rochelle S. Blaustein 

at Rochelle.Blaustein@nih.gov. 

Dated: September 9, 2008. 

Richard U. Rodriguez, 

Director, Division of Technology Development 

and Transfer, Office of Technology Transfer, 

National Institutes of Health. 

[FR Doc. E8–21507 Filed 9–15–08; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Government-Owned Inventions; 

Availability for Licensing 

AGENCY: National Institutes of Health, 

Public Health Service, HHS. 

ACTION: Notice. 

SUMMARY: The inventions listed below 

are owned by an agency of the U.S. 

Government and are available for 

licensing in the U.S. in accordance with 

35 U.S.C. 207 to achieve expeditious 

commercialization of results of 

federally-funded research and 

development. Foreign patent 

applications are filed on selected 

inventions to extend market coverage 

for companies and may also be available 

for licensing. 

ADDRESSES: Licensing information and 

copies of the U.S. patent applications 


ebenthall on PROD1PC60 with NOTICES
53434 Federal Register / Vol. 73, No. 180 / Tuesday, September 16, 2008 / Notices 

listed below may be obtained by writing 

to the indicated licensing contact at the 

Office of Technology Transfer, National 

Institutes of Health, 6011 Executive 

Boulevard, Suite 325, Rockville, 

Maryland 20852–3804; telephone: 301– 

496–7057; fax: 301–402–0220. A signed 

Confidential Disclosure Agreement will 

be required to receive copies of the 

patent applications. 

Cyclized NGR Peptide for Tumor 

Targeting 

Description of Technology: Available 

for licensing and commercial 

development are patent rights and 

materials related to NGR peptides for 

targeting therapeutic and diagnostic 

agents to cancer cells. Specifically 

targeted are tumors that express 

aminopeptidase N isoform CD13. NGR 

peptides include the Asn-Gly-Arg 

peptide motif, a ligand for APN/CD13. 

NGR-containing peptides have been 

proven useful for delivering cytotoxic 

drugs, apoptotic peptides, and cytokines 

(such as tumor necrosis factor (TNF)) to 

tumor vasculature. In some 

embodiments of the invention, the NGR 

peptide is conjugated with a diagnostic 

moiety such as a fluorophore, 

nonmetallic isotope, an optical reporter, 

a boron neutron absorber, a 

paramagnetic metal ion, a ferromagnetic 

metal, a gamma-emitting radioisotope, a 

positron-emitting radioisotope, or an xray absorber. In another embodiment, 

the peptide can be conjugated with a 

therapeutic such as daunorubicin, 

doxorubicin, epirubicin, idarubicin, 

mitoxantrone, or a combination of these. 

The therapeutic agent, such as an antitumor or anti-neoplastic agent of choice, 

can be entrapped within a liposome; the 

liposomes are formulated to be of a size 

known to penetrate the endothelial and 

basement membrane barriers. The 

resulting liposomal formulation can be 

administered parenterally to a subject in 

need of such treatment, preferably by 

intravenous administration. Tumors 

characterized by an acute increase in 

permeability of the vasculature in the 

region of tumor growth are particularly 

suited for treatment by the present 

invention. 

Applications: 

• Cancer diagnostics 

• Cancer therapeutics 

• Anti-angiogenesis 

• Imaging 

Inventors: Bradford Wood, Matthew 

Dreher, Ayele Negussie (CC). 

Relevant Publications: 

1. W Arap et al. Cancer treatment by 

targeted drug delivery to tumor 

vasculature in a mouse model. Science. 

1998 Jan 16;279(5349):377–380. 

2. H Ellerby et al. Anti-cancer activity 

of targeted pro-apoptotic peptides. Nat 

Med. 1999 Sep;5(9):1032–1038. 

3. F Curnis et al. Enhancement of 

tumor necrosis factor alpha antitumor 

immunotherapeutic properties by 

targeted delivery to aminopeptidase N 

(CD13). Nat Biotechnol. 2000 

Nov;18(11):1185–1190. 

4. G Colombo et al. Structure-activity 

relationships of linear and cyclic 

peptides containing the NGR tumorhoming motif. J Biol Chem. 2002 Dec 

6;277(49):47891–47897. 

5. F Pastorino et al. Vascular damage 

and anti-angiogenic effects of tumor 

vessel-targeted liposomal 

chemotherapy. Cancer Res. 2003 Nov 

1;63(21):7400–7409. 


ebenthall on PROD1PC60 with NOTICESEN16SE08.029</GPH>
Federal Register / Vol. 73, No. 180 / Tuesday, September 16, 2008 / Notices 53435 

6. F Pastorino et al. Targeting 

liposomal chemotherapy via both tumor 

cell-specific and tumor vasculaturespecific ligands potentiates therapeutic 

efficacy. Cancer Res. 2006 Oct 

15;66(20):10073–10082. 

7. SV Garde et al. Binding and 

internalization of NGR-peptide-targeted 

liposomal doxorubicin (TVT–DOX) in 

CD13-expressing cells and its antitumor 

effects. Anti-Cancer Drugs. 2007 

Nov;18(10):1189–1200. 

Patent Status: U.S. Provisional 

Application No. 61/074,864 filed 23 Jun 

2008 (HHS Reference No. E–147–2008/ 

0–US–01). 

Licensing Status: Available for 

licensing. 

Licensing Contact: Michael A. 

Shmilovich, Esq.; 301–435–5019; 

shmilovm@mail.nih.gov. 

Microfabricated Particles Useful as 

MRI Contrast Agents 

Description of Technology: MRI 

contrast agents are versatile yet lack the 

sensitivity and multiplexing capabilities 

of optical agents. Available for licensing 

is an invention pertaining to 

microfabricated structures that can be 

used as MRI contrast agents with 

enhanced functionality or as microRFID (radio-frequency identification) 

tags. The microstructures can be 

engineered to appear as different 

effective colors when resolved using 

MRI as opposed to strictly grey-scale 

contrast of existing MRI agents. In this 

way they can be thought as radiofrequency analogs to quantum dots. A 

set of agents could be produced that 

would enable in vivo labeling and 

tracking of multiple different types of 

cells simultaneously. The agents can 

also act as radio-frequency probes of 

various physiological conditions. The 

invention can include a plurality of 

microstructures dispersed a liquid. The 

structures can have magnetic portions 

that vary in size, thickness and shape 

that are arranged to provide a 

substantially uniform Larmor precession 

frequency or a characteristic 

substantially uniform shift in Larmor 

precession frequency experienced by 

nuclear magnetic moments of a material 

when it is located in the substantially 

uniform field region created by the 

magnetic portions. In some 

embodiments, each of the nuclear 

magnetic resonance microstructures has 

a maximum dimension less than about 

1 mm. The magnetic portions of the 

microstructure can be arranged 

proximate to each other, in contact with 

each other or be partially, substantially 

or totally coincident. 

Applications: 

• Magnetic Resonance Imaging 

• Cancer 

• Cardiovascular diseases imaging 

• Drug development 

• Drug candidate distribution tracking 

• Diagnostics 

• Microfluidics 

Inventors: Gary Zabow, Stephen Dodd 

(NINDS), Alan Koretsky (NINDS), John 

Moreland (NIST). 

Publications: 

1. G Zabow et al. Micro-engineered 

local field control for high-sensitivity 

multispectral MRI. Nature 2008 Jun 

19;453(7198):1058–1063. 

2. KA Hinds et al. Highly efficient 

endosomal labeling of progenitor and 

stem cells with large magnetic particles 

allows magnetic resonance imaging of 

single cells. Blood 2003 Aug 

1;102(3):867–872. 

Patent Status: U.S. Provisional 

Application No. 61/071,263 filed 18 Apr 

2008 (HHS Reference No. E–081–2008/ 

0-US–01). 

Licensing Status: Available for 

licensing. 

Licensing Contact: Michael A. 

Shmilovich, Esq.; 301–435–5019; 

shmilovm@mail.nih.gov. 

Collaborative Research Opportunity: 

NINDS Laboratory of Functional and 

Molecular Imaging is seeking statements 

of capability or interest from parties 

interested in collaborative research to 

further develop, evaluate, or 

commercialize the use of 

microfabricated devices as MRI contrast 

agents. Please contact Dr. Melissa 

Maderia at 301–451–3943 or 

maderiam@mail.nih.gov for more 

information. 

Active Guidewire Visualization Device 

and System for MRI Guided 

Interventions 

Description of Technology: Available 

for licensing and commercial 

development is a guidewire device and 

system for MRI guidance of vascular 

interventions. The guidewire design, 

and its coupled system, enables 

interventionalists to visualize the 

location of the tip and distal shaft of an 

MRI compatible guidewire relative to 

the vascular system and surrounding 

anatomy. Visualization of both the shaft 

and tip enables interventionalists to 

advance the guidewire through tortuous 

vessels reducing the risk of puncturing 

vessel walls and also steering it through 

labyrinthine vasculature. The guidewire 

provided by the present invention 

includes distal and proximal ends with 

a space therein, a dipole antenna 

disposed in the space reserved within 

the guidewire body, the dipole antenna 

being adapted to be electrically 

connected to a signal processing system 

through a first signal channel through 

the proximal end of the guidewire body, 

and a loop antenna disposed in the 

space reserved within the guidewire 

body toward the distal end of the 

guidewire body, the loop antenna being 

adapted to be electrically connected to 

the signal processing system through a 

second signal channel through the 

proximal end of the guidewire body. 

The dipole antenna and the loop 

antenna are each constructed to receive 

magnetic resonance imaging signals 

independently of each other and to 

transmit received signals through the 

first and second signal channels, 

respectively, to be received by the signal 

processing system. More specifically, 

both loop and dipole antenna are tuned 

to resonate at the same Larmour 

frequency as produced by the magnet. 

Applications: 

• Interventional cardiology 

• MRI guided surgery 

Inventors: Ozgur Kocaturk (NHLBI). 

Publications: 

1. McKinnon GC, et al. Towards 

active guidewire visualization in 

interventional magnetic resonance 

imaging. MAGMA. 1996 Mar;4(1):13–18. 

2. Ladd ME, et al. Active MR 

visualization of a vascular guidewire in 

vivo. J Magn Reson Imaging. 1998 JanFeb;8(1):220–225. 

Patent Status: U.S. Provisional 

Application No. 61/006,265 filed 03 Jan 

2008 (HHS Reference No. E–209–2007/ 

0-US–01) 

Licensing Status: Available for 

licensing. 

Licensing Contact: Michael A. 

Shmilovich, Esq.; 301–435–5019; 

shmilovm@mail.nih.gov. 

Collaborative Research Opportunity: 

The National Institutes of Health / 

Cardiac Catheter Core Lab is seeking 

statements of capability or interest from 

parties interested in collaborative 

research to further develop, evaluate, or 

commercialize Active two channel 

0.035′′ guidewire. Please contact Ozgur 

Kocaturk at 301–402–9430 or 

kocaturko@nhlbi.nih.gov. 

Respiratory Syncytial Virus (RSV) 

Vaccines Based on Promoter-Proximate 

Attenuation 

Description of Technology: Available 

for licensing and commercial 

development is a patent estate and 

related biological materials for 

producing therapeutic or prophylactic 

vaccines against Respiratory Syncytial 

Virus (RSV). The claimed vaccine 

strategy relates to the engineering and 

creation of live-attenuated RSV vaccine 

candidates by shifting the position of 

one or more viral genes relative to the 

viral promoter (aka promoter-proximal 


ebenthall on PROD1PC60 with NOTICES
53436 Federal Register / Vol. 73, No. 180 / Tuesday, September 16, 2008 / Notices 

attenuation). The gene shifts can be 

constructed by insertion, deletion or 

rearrangement of genes or genome 

segments within the recombinant 

genome or antigenome. Viral replication 

can increase or decrease depending on 

the position of expressed viral gene and 

depending on the nature and degree of 

the positional shift. Viral gene 

rearrangements are selected to maintain 

sufficient non-infectious replication of 

RSV while eliciting host anti-RSV 

immune responses. Viral genes targeted 

for such rearrangement include any of 

the NS1, NS2, N, P, M, SH, M2(ORF1), 

M2(ORF2), L, F or G genes or genome 

segment. 

One modification of particular 

interest is the placement of the G and F 

protective antigen genes in a promoterproximal position for increased 

expression. The gene position-shifted 

RSV can be further manipulated by the 

addition of specific nucleotide and 

amino acid point mutations or host 

range restriction determinants to yield 

desired phenotypic and structural 

effects. 

Applications: 

• Infectious Disease—Respiratory 

Syncytial Virus 

• Vaccines 

• Therapeutics 

• Prophylactics 

• Childhood Vaccines 

Inventors: Christine D. Krempl, Peter 

L. Collins, Brian R. Murphy, Ursula 

Buchholz, Stephen S. Whitehead 

(NIAID) 

Publications: 

1. C Krempl et al. Recombinant 

respiratory syncytial virus with the G 

and F genes shifted to the promoterproximal positions. J Virol. 2002 

Dec;76(23):11931–11942. 

2. Y Aloni, N Hay. Attenuation may 

regulate gene expression in animal 

viruses and cells. CRC Crit Rev 

Biochem. 1985;18(4):327–383. 

Patent Status: 

HHS Reference No. E–225–2000/0— 

• U.S. Patent No. 6,923,971 issued 02 

Aug 2005 

• U.S. Patent Application No. 11/ 

033,055 filed 10 Jan 2005 

• U.S. Patent Application No. 11/ 

054,343 filed 08 Feb 2005 

• International Patent Application 

PCT/US2001/20107, which 

published as WO 2002/00693 on 03 

Jan 2002 (expired) 

• Australian Patent 2001268709 

• Brazilian Patent Application 

PI0112276–2 

• Canadian Patent Application 

2413786 

• Chinese Patent Application 

01814362.8 

• European Patent Application 

01946696.0 

• Israeli Patent Application 153530 

• Japanese Patent Application 10– 

2002–505815 

• Korean Patent Application 10– 

2002–7017577 and 

• Mexican Patent Application 2002– 

012818. 

Licensing Status: Available for 

licensing. 

Licensing Contact: Michael A. 

Shmilovich, Esq.; 301–435–5019; 

shmilovm@mail.nih.gov. 

Collaborative Research Opportunity: 

The NIAID Office of Technology 

Development is seeking statements of 

capability or interest from parties 

interested in collaborative research to 

further develop, evaluate, or 

commercialize live attenuated vaccines. 

Please contact Michael Piziali at 301– 

451–3527 for more information. 

Quantitative Assessment of Changes in 

Tissue Status in Disease, Development, 

Aging, or Degeneration Using Diffusion 

Tensor Magnetic Resonance Imaging 

Description of Technology: This 

invention significantly enhances the 

quality and utility of diffusion tensor 

magnetic resonance imaging (DT-MRI) 

data. The patent application for the 

invention describes quantitative 

statistical methodology to extract novel 

clinical and biological information from 

DT-MRI data. These parametric and 

non-parametric statistical methods help 

distinguish changes in tissue state from 

background noise inherent in all MRI 

measurements. The invention also 

includes hypothesis tests to determine 

the statistical significance of changes 

observed in MRI ‘‘stains’’ (e.g., the Trace 

of the diffusion tensor, Trace(D), and the 

mean apparent diffusion coefficient, 

ADC), which are widely used in the 

diagnosis of stroke. Further, this 

invention describes how to detect 

systematic artifacts in each pixel of a 

diffusion weighted image (e.g., artifacts 

caused by patient motion). Indeed, this 

new statistical methodology for 

analyzing and interpreting diffusion 

tensor MRI data should improve the 

efficacy of drug screening studies, as 

well as streamline multi-site and 

longitudinal studies designed to assess 

the safety and efficacy of drugs 

undergoing clinical evaluation. 

Inventors: Peter J. Basser (NICHD), 

Sinisa Pajevic (CIT). 

Patent Status: U.S. Patent No. 

6,845,324 issued 15 Jan 2005 (HHS 

Reference No. E–192–1999/0-US–07) 

Licensing Status: Available for 

licensing. 

Licensing Contact: Michael A. 

Shmilovich, Esq.; 301–435–5019; 

shmilovm@mail.nih.gov. 

Human-Bovine Chimeric Respiratory 

Syncytial Virus (RSV) Vaccines 

Description of Technology: Available 

for licensing and commercial 

development is a patent estate and 

related biological materials for making 

human-bovine chimeric virus particles 

for formulating live attenuated vaccines 

against human respiratory syncytial 

virus (RSV). Chimeric human-bovine 

RSVs are recombinantly engineered to 

incorporate nucleotide sequences from 

both human and bovine RSV strains and 

produce infectious, chimeric viruses 

that elicit anti-RSV immunological 

responses in humans and non-human 

primates. The chimeras incorporate 

partial or complete human or bovine 

RSV background genomes with one or 

more recombinantly integrated 

heterologous genes or genome segments 

of a different RSV strain. 

Heterologous genes of interest for 

making chimeric recombinants include 

NS1, NS2, N, P, M, SH glycoprotein (or 

an immunogenic domain or epitope 

thereof), M2(ORF1), M2(ORF2), L, F or 

G genes or a genome segment including 

a protein or portion thereof or 

alternatively a leader, trailer or 

intergenic region of the RSV genome, or 

a segment thereof. A variety of 

additional mutations and nucleotide 

modifications are provided within the 

human-bovine chimeric RSV of the 

invention to yield desired phenotypic 

and structural effects. Exemplary 

human-bovine chimeric RSV of the 

invention incorporate a chimeric RSV 

genome or antigenome comprising both 

human and bovine polynucleotide 

sequences, as well as a major 

nucleocapsid (N) protein, a 

nucleocapsid phosphoprotein (P), a 

large polymerase protein (L), and an 

RNA polymerase elongation factor. 

Additional RSV proteins may be 

included in various combinations to 

provide a range of infectious subviral 

particles up to a complete viral particle 

or a viral particle containing 

supernumerary proteins, antigenic 

determinants or other additional 

components. 

Applications: 

• Infectious Disease—Respiratory 

Syncytial Virus 

• Vaccines 

• Therapeutics 

• Prophylactics 

• Childhood Vaccines 

Inventors: Ursula Buchholz, Peter L. 

Collins, Brian R. Murphy, Stephen S. 

Whitehead, Christine D. Krempl 

(NIAID). 


ebenthall on PROD1PC60 with NOTICES
Federal Register / Vol. 73, No. 180 / Tuesday, September 16, 2008 / Notices 53437 

Publications: 

1. UJ Buchholz et al. Chimeric bovine 

respiratory syncytial virus with 

glycoprotein gene substitutions from 

human respiratory syncytial virus 

(HRSV): effects on host range and 

evaluation as a live-attenuated HRSV 

vaccine. J Virol. 2000 Feb;74(3):1187– 

1199. 

2. A Karger et al. Recombinant bovine 

respiratory syncytial virus with 

deletions of the G or SH genes: G and 

F proteins bind heparin. J Gen Virol. 

2001 Mar;82(Pt 3):631–640. 

3. UJ Buchholz et al. Generation of 

bovine respiratory syncytial virus 

(BRSV) from cDNA: BRSV NS2 is not 

essential for virus replication in tissue 

culture, and the human RSV leader 

region acts as a functional BRSV 

genome promoter. J Virol. 1999 

Jan;73(1):251–259. 

Patent Status: 

HHS Reference No. E–178–1999/0— 

• International Patent Application 

PCT/US00/17755, which published 

as WO 2001/04335 on 09 Jan 2001 

(expired) 

• Australian Patent 784216 

• Chinese Patent 00810119.1 

• Canadian Patent Application 

2378552 

• European Patent Application 

00941756.9 

• Israeli Patent Application 147447 

• Japanese Patent Application 2001– 

509539 

• Korean Patent Application 10– 

2002–7000318 

• Mexican Patent Application 2002– 

000220 

• Brazilian Patent Application 

PI0013195–4 and 

• Chinese Patent Application 

200710167112.6 

HHS Reference No. E–178–1999/1— 

• U.S. Patent Application No. 11/ 

097,946 filed 31 Mar 2005 

HHS Reference No. E–178–1999/2— 

• U.S. Patent Application No. 10/ 

704,116 filed 07 Nov 2003 

Licensing Status: Available for 

licensing. 

Licensing Contact: Michael A. 

Shmilovich, Esq.; 301–435–5019; 

shmilovm@mail.nih.gov. 

Collaborative Research Opportunity: 

The NIAID Office of Technology 

Development is seeking statements of 

capability or interest from parties 

interested in collaborative research to 

further develop, evaluate, or 

commercialize attenuated live vaccines 

against respiratory syncytial virus 

(RSV). Please contact Barry Buchbinder 

at 301–594–1696 for more information. 

Dated: September 9, 2008. 

Richard U. Rodriguez, 

Director, Division of Technology Development 

and Transfer, Office of Technology Transfer, 

National Institutes of Health. 

[FR Doc. E8–21519 Filed 9–15–08; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Cancer Institute; Notice of 

Meeting 

Pursuant to section 10(a) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. Appendix 2), notice 

is hereby given of a meeting of the 

National Cancer Institute Director’s 

Consumer Liaison Group. 

The meeting will be open to the 

public, with attendance limited to space 

available. Individuals who plan to 

attend and need special assistance, such 

as sign language interpretation or other 

reasonable accommodations, should 

notify the Contact Person listed below 

in advance of the meeting. 

Name of Committee: National Cancer 

Institute Director’s Consumer Liaison Group. 

Date: October 14–15, 2008. 

Time: 8 a.m. to 5 p.m. 

Agenda: (1) Approval of Minutes; (2) 

Report from Dr. John Niederhuber, NCI 

Director; (3) Report on the OAR; (4) Report 

from Planning & Office of Governmental & 

Congressional Relations OD/NCI; (5) Indian 

Health Service & Cancer Issues of Native 

Americans; (6) Cancer Health 

Communications; (7) Update-NCI 

Community Cancer Clinics Program; (8) 

Reports from DCLG Working Groups & 

Member Updates; (9) Public Comment; (10) 

Action Items/Conclusion. 

Place: National Institutes of Health, 

Building 31, Conference Room 6, 31 Center 

Drive, Bethesda, MD 20892. 

Contact Person: Shannon K. Bell, MSW, 

Executive Secretary, National Cancer 

Institute, National Institutes of Health, 31 

Center Drive, Building 31, Room 10A30D, 

Bethesda, MD 20892, 301–451–3393. 

Any interested person may file written 

comments with the committee by forwarding 

the statement to the Contact Person listed on 

this notice. The statement should include the 

name, address, telephone number and when 

applicable, the business or professional 

affiliation of the interested person. 

In the interest of security, NIH has 

instituted stringent procedures for entrance 

onto the NIH campus. All visitor vehicles, 

including taxicabs, hotel, and airport shuttles 

will be inspected before being allowed on 

campus. Visitors will be asked to show one 

form of identification (for example, a 

government-issued photo ID, driver’s license, 

or passport) and to state the purpose of their 

visit. 

Information is also available on the 

Institute’s/Center’s home page: http:// 

deainfo.nci.nih.gov/advisory/dclg/dclg.htm, 

where an agenda and any additional 

information for the meeting will be posted 

when available. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.392, Cancer Construction; 

93.393, Cancer Cause and Prevention 

Research; 93.394, Cancer Detection and 

Diagnosis Research; 93.395, Cancer 

Treatment Research; 93.396, Cancer Biology 

Research; 93.397, Cancer Centers Support; 

93.398, Cancer Research Manpower; 93.399, 

Cancer Control, National Institutes of Health, 

HHS) 

Dated: September 9, 2008. 

Jennifer Spaeth, 

Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. E8–21499 Filed 9–15–08; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Cancer Institute; Notice of 

Meeting 

Pursuant to section 10(a) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. Appendix 2), notice 

is hereby given of a meeting of the 

National Cancer Institute Board of 

Scientific Advisors. 

The meeting will be open to the 

public, with attendance limited to space 

available. Individuals who plan to 

attend and need special assistance, such 

as sign language interpretation or other 

reasonable accommodations, should 

notify the Contact Person listed below 

in advance of the meeting. 

Name of Committee: National Cancer 

Institute Board of Scientific Advisors. 

Date: November 6–7, 2008. 

Time: November 6, 2008, 8 a.m. to 6 p.m. 

Agenda: Director’s Report: Ongoing and 

New Business; Reports of Program Review 

Group(s); and Budget Presentation; Reports of 

Special Initiatives; RFA and RFP Concept 

Reviews; and Scientific Presentations. 

Place: National Institutes of Health, 

Building 31, 31 Center Drive, 6th Floor, 

Conference Room 10, Bethesda, MD 20892. 

Time: November 7, 2008, 8:30 a.m. to 

12 p.m. 

Agenda: Reports of Special Initiatives; RFA 

and RFP Concept Reviews; and Scientific 

Presentations. 

Place: National Institutes of Health, 

Building 31, 31 Center Drive, 6th Floor, 

Conference Room 10, Bethesda, MD 20892. 

Contact Person: Paulette S. Gray, PhD, 

Executive Secretary, Director, Division of 

Extramural Activities, National Cancer 

Institute, National Institutes of Health, 6116 

Executive Boulevard, 8th Floor, Rm. 8001, 

Bethesda, MD 20892, 301–496–5147, 

grayp@mail.nih.gov. 

Any interested person may file written 

comments with the committee by forwarding 


ebenthall on PROD1PC60 with NOTICES